Physician profile
Susan Brown
NPI 1003805375
$2,542.19
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,542.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $294.33 | 2019 | |
| Genentech USA, INC. | $196.30 | 2019 | |
| Novartis Pharmaceuticals Corporation | $180.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $158.55 | 2019 | |
| Merck Sharp & Dohme LLC | $141.01 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $130.79 | 2019 | |
| Tesaro, INC. | $121.62 | 2019 | |
| Genzyme Corporation | $97.94 | 2019 | |
| Pfizer INC. | $95.87 | 2019 | |
| Octapharma USA, INC. | $91.28 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $91.22 | 2019 | |
| Celgene Corporation | $82.55 | 2019 | |
| Incyte Corporation | $72.78 | 2019 | |
| Astellas Pharma US INC | $64.08 | 2019 | |
| Daiichi Sankyo INC. | $61.87 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $51.36 | 2019 | |
| Lilly USA, LLC | $50.72 | 2019 | |
| Janssen Pharmaceuticals, INC | $50.57 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.95 | 2019 | |
| Seagen INC. | $47.45 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $45.14 | 2019 | |
| Taiho Oncology, INC. | $41.11 | 2019 | |
| Emd Serono, INC. | $38.18 | 2019 | |
| Janssen Biotech, INC. | $35.99 | 2019 | |
| Eisai INC. | $32.06 | 2019 | |
| Array Biopharma INC | $22.68 | 2019 | |
| Exelixis INC. | $22.42 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $19.85 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.26 | 2019 | |
| Foundation Medicine, INC. | $17.87 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $16.84 | 2019 | |
| Tersera Therapeutics LLC | $16.36 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $16.04 | 2019 | |
| Puma Biotechnology, INC. | $14.51 | 2019 | |
| Clovis Oncology, INC. | $14.05 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.02 | 2019 | |
| Mayne Pharma Commercial LLC | $13.41 | 2019 | |
| Verastem, INC. | $12.45 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.